Cruise Ship Outbreak Sparks Hope for Neglected Hantavirus Vaccine

A hantavirus outbreak aboard the MV Hondius cruise ship has intensified efforts to develop a vaccine against the virus. Experts point out that vaccine development has historically stalled due to the sporadic nature of outbreaks and their disproportionate impact on less affluent nations, which offer little incentive for pharmaceutical investment.

Sabra Klein of Johns Hopkins University noted that funding agencies deprioritize these viruses, despite their potential to cause severe illness and widespread destruction. EnsiliTech, a U.K.-based biotech firm, has been working on an mRNA vaccine for 15 years, seeing hantavirus as a neglected area with no prior significant research.

EnsiliTech's vaccine utilizes messenger RNA technology, the same platform behind COVID-19 vaccines. It targets the hantaan virus strain prevalent in East Asia, responsible for hemorrhagic fever with renal syndrome. A key innovation is its room-temperature transport capability, achieved through a proprietary "ensilication" method that encases mRNA in a silica cage, addressing a major logistical hurdle faced by early COVID-19 vaccines.

While trials in rodents have been successful, human testing is estimated to be three to four years away. The development timeline could be significantly shortened to about five years for Phase 2 and 3 trials if similar support to Operation Warp Speed is provided. Other hantavirus vaccines are in preclinical stages, but none have reached human trials.

Dr. Ofer Levy of Boston Children's Hospital mentioned that China and South Korea have vaccines with mixed results, unavailable elsewhere. Historically, the U.S. military has shown interest due to past exposure, but sporadic global outbreaks have hindered funding. Without substantial commercial interest or dedicated initiatives, the widespread availability of a hantavirus vaccine remains a distant prospect.